Stay updated with the latest allosteric-regulation news, articles, and insights from trusted sources. Explore in-depth coverage and expert analysis on allosteric-regulation topics.
BETHESDA, Md. - Gain Therapeutics, Inc. (NASDAQ:GANX), a $69 million market cap biotech company currently trading at $1.92 per share, announced Monday that its lead drug candidate GT-02287 showed encouraging early results in a Phase 1b clinical study for Parkinson's disease patients. According to InvestingPro data, the company maintains a strong balance sheet with more cash than debt, though it's currently experiencing rapid cash burn typical of early-stage biotechs. The company presented inter ...Read More >
Stay updated with the latest None news, articles, and insights from trusted sources. Explore in-depth coverage and expert analysis on None topics.